Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill

Xue Liu; Wenjing Ning; Lei Wang; Han Liu; Hongye Zeng; Xiaojing Qin; Yuanzhi Chen; Fentian Chen; Lin Xu; Yang Zhao; Xiaoqing Chen; Jixian Tang; Yunlong Ren; Xiaowen Yan; Wenxin Luo; Ningshao Xia

doi:10.1002/cac2.12616

Cancer Communications ›› 2024, Vol. 44 ›› Issue (12) : 1444 -1448. DOI: 10.1002/cac2.12616

LETTER TO THE JOURNAL

Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill

Xue Liu ¹^,²
, Wenjing Ning ¹^,²
, Lei Wang ³
, Han Liu ¹^,²
, Hongye Zeng ¹^,²
, Xiaojing Qin ¹^,²
, Yuanzhi Chen ¹^,²
, Fentian Chen ¹^,²
, Lin Xu ¹^,²
, Yang Zhao ³
, Xiaoqing Chen ¹^,²
, Jixian Tang ¹^,²
, Yunlong Ren ¹^,²
, Xiaowen Yan ³^,⁴^,^†
, Wenxin Luo ¹^,²^,^†
, Ningshao Xia ¹^,²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Xue Liu, Wenjing Ning, Lei Wang, Han Liu, Hongye Zeng, Xiaojing Qin, Yuanzhi Chen, Fentian Chen, Lin Xu, Yang Zhao, Xiaoqing Chen, Jixian Tang, Yunlong Ren, Xiaowen Yan, Wenxin Luo, Ningshao Xia. Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill. Cancer Communications, 2024, 44(12): 1444-1448 DOI:10.1002/cac2.12616

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023; 22(8): 641–661.

[2]	Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023; 20(8): 558–576.

[3]	Passaro A, Jänne PA, Peters S. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol. 2023; 41(21): 3747–3761.

[4]	Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024; 21(3): 203–223.

[5]	Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8): 583–592.

[6]	Strack R. Nanobodies made versatile. Nat Methods. 2023; 20(1): 37.

[7]	Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82: 775–797.

[8]	Wu Y, Li Q, Kong Y, Wang Z, Lei C, Li j, et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022; 30(8): 2785–2799.

[9]	Gan X, Shan Q, Li H, Janssens R, Shen Y, He Y, et al. An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile. Proc Natl Acad Sci U S A. 2022; 119(32): e2200879119.

[10]	Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, et al. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnology. 2023; 21(1): 410.